Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com |
February 20, 2020
Corporate Relationship Department | National Stock Exchange of India Ltd. |
BSE Limited | “Exchange Plaza” |
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
Mumbai – 400 001 | Mumbai – 400 051 |
Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
22722037 / 22722039 | 26598238 |
|
|
Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Intimation
Further to our intimations dated August 20, 2019 and February 16, 2020 with regard to the audit of our Formulations Manufacturing Plant (“Vizag SEZ Plant 1 - FTO 7”) at Duvvada, Visakhapatnam, we would like to inform you that we have received the Establishment Inspection Report (EIR) from US FDA, for the above-referred facility, indicating closure of the audit. As intimated earlier the facility has been classified as VAI (Voluntary Action Indicated)
This is for your information.
With regards,
/s/ Vikas Sabharwal |
|
Vikas Sabharwal |
|
Assistant Company Secretary |
|
CC:- New York Stock Exchange Inc.(Stock Code :RDY)